CutPRO® Cut Resistant Clothing Sponsoring Leading Glass Event ‘Glass Focus 2019’
British firm CutPRO® is sponsoring this year’s ‘Glass Focus 2019’ event taking place on 21 November in Sheffield, United Kingdom.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191119005029/en/
CutPRO® is a pioneering British brand of high performance cut resistant clothing, providing fully CE certified, EN 388:2016 tested and thoroughly field tested cut protection. (Graphic: Business Wire)
Robert Kaiser, CEO of PPSS Group, the firm behind the CutPRO® brand, also announced it had entered the ‘Health and Safety Action’ category: “We have high hopes to win this prestigious award. Our innovative and pioneering brand of high performance cut resistant clothing somewhat deserves that level of recognition”.
The event is organised by ‘British Glass’, the representative body for the UK industry. Communicating the glass sector’s values and interests, their aim is to secure a thriving and sustainable future.
UK based PPSS Group has been producing cut resistant clothing for the past ten years, its sole purpose being the protection of frontline professionals in sectors where cuts and lacerations are a high risk e.g. homeland security.
In February 2018 the now highly acclaimed CutPRO® brand was launched, again using their very own Cut-Tex® PRO cut resistant fabric. Cut-Tex® PRO has achieved outstanding levels of cut, tear, abrasion and puncture resistance, while being extremely durable, lightweight and rather comfortable.
As a single layer it is offering ANSI/ISEA 2016 Blade Cut Resistance Level A5.
CutPRO®s Senior Product Consultant Eve Ichim operated as a liaison between potential customers and the firm’s production team, gathering relevant information about precise requirements and preferences for cut resistant clothing.
Based on this information, extensive market research and working together with the multi-award-winning Department of Apparel from one UK’s leading Universities, CutPRO® is now offering the ultimate garment designs, taking 'durability' and 'quality' to a completely different level.
All garments are manufactured in the E.U. and are fully CE marked and certified (Cat II PPE). This means they fully comply with European laws, rules and regulations.
All garments have also been successful assessed against the updated and latest EN 388:2016 standard, confirming the following performance levels: Cut Resistance Level E (Level 5 on previous standard). Puncture Resistance Level 4. Tear Resistance Level 4. Abrasion Resistance Level 3.
If you are planning to attend the ‘Glass Focus 2019’ go and say hi to their team. You will be welcomed with open arms and an immense level of technical knowledge.
Robert Kaiser has also recently announced his company’s participation at next year’s glasstec2020 Expo in Dusseldorf, Germany:
"We have decided to present and exhibit our truly outstanding cut resistant clothing range at glasstec2020, the world’s largest and most respected Exhibition within the glass industry."
"There is no better platform for us to showcase our range of potentially lifesaving cut resistant garments to the world."
In case you have any questions in reference to cut resistant clothing, please email info@cut-pro.com or visit www.cut-pro.com.
END
About CutPRO®
CutPRO® Cut Resistant Clothing is a pioneering brand of highly protective clothing. Made from the world’s most reliable, fully certified and thoroughly field-tested cut resistant fabric Cut-Tex® PRO. The company’s social media presence: Facebook, LinkedIn, Twitter and Instagram.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191119005029/en/
Contact information
Ryan Vickers, CDO
PPSS Group / CutPRO®
info@ppss-group.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Lone Star Announces Sale of Xella to Holcim20.10.2025 07:40:00 EEST | Press release
Lone Star Funds (“Lone Star”) today announced the signing by an affiliate of Lone Star Fund X, LP of a binding agreement to sell Xella Group (“Xella”), a leading provider of walling solutions, to Holcim, the leading partner for sustainable construction. The transaction values Xella at approximately €1.85 billion. Headquartered in Duisburg, Germany, Xella is a European provider of efficient and sustainable walling solutions for the entire house shell, operating brands such as Ytong, Silka, Hebel and Multipor. The company employs more than 4,000 team members. In partnership with Lone Star, Xella has taken significant strides in recent years to optimize its offering by strategically focusing the business on walling solutions, while also enhancing its commercial and digital capabilities. Under Lone Star’s stewardship, Xella has also continued to progress its sustainability initiatives. Today, the business stands as a market leader in its sector with a strong reputation for a people-first c
Worldwide First: Biedermann Motech Further Expands its MOSS!MODULARITY Platform and Announces Introduction of Multiple New Products20.10.2025 07:00:00 EEST | Press release
Biedermann Motech, the prominent innovator in next generation spinal and extremity implant systems and procedural solutions, today announced the market introduction of several additions to its MOSS!MODULARITY™ platform. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251019799867/en/ MOSS!MODULARITY Injection Screw MOSS!MODULARITY encompasses a broad range of products and technologies for spinal surgery based around the concept of providing an advanced modular workflow for posterior stabilization and deformity correction. The modular workflow allows surgeons to place the headless bone screw shafts as a first step, without the tulip heads attached, and offers several advantages over working with traditional pre-assembled pedicle screws, e.g.: Improved visualisation and access to the surgical working space; Precise decompression, decortication and osteotomies without any interference with polyaxial tulip heads; Increased surgic
Incyte Announces Phase 1 Results for its TGFβR2×PD-1 Bispecific Antibody in Advanced Colorectal Cancer and KRAS G12D Inhibitor in Advanced Pancreatic Ductal Adenocarcinoma19.10.2025 20:30:00 EEST | Press release
Incyte (Nasdaq:INCY) announced the first clinical data evaluating its TGFβR2×PD-1 bispecific antibody (INCA33890) for patients with microsatellite stable (MSS) colorectal cancer; and its potent, selective and orally bioavailable KRAS G12D inhibitor (INCB161734) for patients with KRAS G12D mutations, specifically pancreatic ductal adenocarcinoma (PDAC). The data were featured in two oral sessions (Investigational immunotherapy; Abstract #1522MO and Developmental therapeutics; Abstract #916O, respectively) at the European Society of Medical Oncology (ESMO) Congress 2025. “The proof-of-concept data highlight the potential of INCA33890 and INCB161734 to address significant medical needs in patients with advanced solid tumors, including MSS colorectal cancer and PDAC,” said Pablo J. Cagnoni, M.D., President and Head of Research and Development, Incyte. “These results, including the favorable safety profiles as monotherapies, support continued clinical development. We look forward to explori
Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment19.10.2025 12:15:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today shared new late-breaking data from its pivotal Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer at the European Society for Medical Oncology (ESMO) 2025 Annual Meeting. The data demonstrated a progression-free survival (PFS) benefit for patients who experienced disease progression while on or after taking a PARP inhibitor (PARPi), a patient population with particularly poor prognosis. The presentation slides can be found here. The company also announced expansion of the Phase 2 BELLA trial in a poster session at ESMO, found here. New relacorilant data presented at ESMO demonstrated a consistent benefit in PARPi subgroups to overcome chemotherapy resistance. Relaco
Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA ™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 14:00:00 EEST | Press release
Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the durable benefit that vimseltinib can offer patients.” Summary of Data and Findings from the 2-year results of the MOTION Phase
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom